Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jun. 2026,
PT Bundamedik Tbk paidRp0 Mil more to buy back shares than it received from issuing new shares.
It receivedRp101,581 Mil from issuing more debt.
It paidRp0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedRp0 Mil from paying cash dividends to shareholders.
It receivedRp12,801 Mil on other financial activities.
In all, PT Bundamedik TbkearnedRp114,382 Mil on financial activities for the
three
months ended in Jun. 2026.
PT Bundamedik Tbk (ISX:BMHS) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
PT Bundamedik Tbk's issuance of stock for the
three
months ended in Jun. 2026 was Rp0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
PT Bundamedik Tbk's repurchase of stock for the
three
months ended in Jun. 2026 was Rp0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
PT Bundamedik Tbk's net issuance of debt for the
three
months ended in Jun. 2026 was Rp101,581 Mil.
PT Bundamedik Tbk receivedRp101,581 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
PT Bundamedik Tbk's net issuance of preferred for the
three
months ended in Jun. 2026 was Rp0 Mil.
PT Bundamedik Tbk paidRp0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
PT Bundamedik Tbk's cash flow for dividends for the
three
months ended in Jun. 2026 was Rp0 Mil.
PT Bundamedik Tbk receivedRp0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
PT Bundamedik Tbk's other financing for the
three
months ended in Jun. 2026 was Rp12,801 Mil.
PT Bundamedik Tbk receivedRp12,801 Mil on other financial activities.
PT Bundamedik Tbk Cash Flow from Financing Related Terms
PT Bundamedik Tbk Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
PT Bundamedik Tbk's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp144,999 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of Rp144,999 Mil mean?
PT Bundamedik Tbk (ISX:BMHS) has a Cash Flow from Financing of Rp144,999 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PT Bundamedik Tbk and its competitors.
Is PT Bundamedik Tbk's Cash Flow from Financing too high?
PT Bundamedik Tbk's current Cash Flow from Financing is Rp144,999 Mil. Overall, PT Bundamedik Tbk has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Cash Flow from Financing compare to HCA and THC?
PT Bundamedik Tbk's Cash Flow from Financing of Rp144,999 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PT Bundamedik Tbk and its competitors. PT Bundamedik Tbk's current Cash Flow from Financing is Rp144,999 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp265.35, compared to a current price of Rp194.00 — trading 26.9% below its estimated fair value. The current Cash Flow from Financing is Rp144,999 Mil. PT Bundamedik Tbk's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Cash Flow from Financing is Rp144,999 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp194.00 is trading 26.9% below its estimated GF Value™ of Rp265.35.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
Cash Flow from Financing: Rp144,999 Mil
GF Value™: Rp265.35 vs. price of Rp194.00 (26.9% below fair value)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
67GF Score
Get the complete analysis for ISX:BMHS
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
